Address
Manfred Eigen Campus
Essener Bogen 7
Hamburg
22419 Germany
Contact
Aurelie Couturier+4407736276005
Aurelie.Couturier@evotec.com
Website
Download PDF
Comprehensive antimicrobial drug discovery
Evotec leverages advanced platforms, including AI-driven drug discovery, high-throughput screening, and molecular design, to accelerate the development of therapies targeting bacteria, viruses, and fungi from early discovery to clinical stages.
Evotec offers a unique, integrated approach, combining AI-driven discovery, HTS, and advanced bioinformatics to identify promising drug candidates efficiently. The EvostrAIn™ collection and our expertise in resistance mechanism analysis, SAR profiling, and specialized models enhance precision in targeting pathogens. With robust PK/PD assays and comprehensive platforms in DMPK, immunology, and toxicology, we accelerate lead optimization and pre-IND readiness, reducing time-to-clinic.
- Infection prevention
- Antimicrobial compound/strategy
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Other
- Environmental
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- CARB-X
- FIND
- GARDP
- REPAIR
- OTHER / NA
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
In-licence assets, buy your service
Evotec is a global life sciences company focused on discovering, developing, and manufacturing innovative therapies for various medical conditions. Operating as a drug discovery and development partner, Evotec collaborates with leading pharmaceutical, biotech, academic, and non-profit organizations worldwide. Its core expertise lies in integrating cutting-edge science and technology across diverse therapeutic areas such as oncology, metabolic disorders, and infectious diseases.
Evotec leverages AI, machine learning, and advanced biological research to accelerate drug discovery and deliver comprehensive R&D solutions.
Key numbers as of recent data:
• Headquarters: Hamburg, Germany
• Employees: ~4,000 across multiple sites in Europe and the U.S.
• Revenue: Approximately €750 million annually
• Partnerships: Over 500 collaborations with industry leaders, including Bayer, Bristol-Myers Squibb, and Sanofi
• R&D Investment: Around €150 million annually in proprietary and partnered projects
Beyond infectious diseases, Evotec provides comprehensive drug discovery and development services across various therapeutic areas, including oncology, neurology, and metabolic disorders. Key platforms include pluripotent stem cell (iPSC) technology for disease modelling, advanced proteomics, CRISPR-based gene editing, and biomarker discovery. Our capabilities span target identification, HTS, medicinal chemistry, DMPK, and toxicology, supporting partners from early research to clinical trials.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!